Search

Your search keyword '"Borel C"' showing total 88 results

Search Constraints

Start Over You searched for: Author "Borel C" Remove constraint Author: "Borel C" Publisher elsevier bv Remove constraint Publisher: elsevier bv
88 results on '"Borel C"'

Search Results

6. LBA35 Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Randomized phase III GORTEC-REACH trial

7. Mucoepidermoid carcinoma of salivary glands: A French Network of Rare Head and Neck Tumors (REFCOR) prospective study of 292 cases

9. 925P Efficacy of 2nd line treatment with chemotherapy (CT) or immune checkpoint inhibitors (ICIs) for patients (pts) with a prolonged objective response (>6 months) after 1st line therapy for recurrent or metastatic head & neck squamous cell carcinoma (R/M-HNSCC)

10. 914MO Standard versus fractionated high dose cisplatin concomitant with radiotherapy in locally advanced head & neck squamous cell cancer (LA-HNSCC): Results of the GORTEC 2015-02 CisFRad randomized trial

11. 930P Weekly paclitaxel, carboplatin and cetuximab (PCC) as first-line treatment of recurrent and/or metastatic head & neck squamous cell carcinoma (R/M-HNSCC) for patients ineligible to cisplatin based chemotherapy

12. Oncologic outcomes, prognostic factor analysis and therapeutic algorithm evaluation of head and neck mucosal melanomas in France

14. Impact of concomitant medications on disease free survival (DFS) and overall survival (OS) in patients from the PETACC8 study

15. Vemurafenib in patients (pts) harboring BRAF V600 mutation: Results of non-small cell lung cancer (NSCLC) cohort from the AcSé trial

16. M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients (pts) with advanced SCCHN: Results from a phase I cohort

17. TOPNIVO: A safety study of nivolumab in patients with recurrent and/or metastatic platinum-refractory squamous cell carcinoma of the head and neck (R/M SCCHN): First results on behalf of the UNICANCER Head&Neck Group and the GORTEC

19. Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults

20. Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials

21. Les doigts du grimpeur

22. Predictive factors for early progression during induction chemotherapy (IC) and chemotherapy-free interval (CFI): Analysis from PRODIGE 9 trial

23. Recurrent or metastatic head and neck squamous cell carcinoma (RM HNSCC): What about second-line chemotherapy combining cetuximab and platinum-doublet after EXTREME protocol?

25. Pazopanib in patients with progressive recurrent or metastatic (R/M) salivary gland carcinoma (SGC): Further evaluation of efficacy including tumor growth rates (GR) analysis. H&N Unicancer Group PACSA trial with the REFCOR

30. Analysis of the hydrographic conditions and cyst beds in the San Jorge Gulf, Argentina, that favor dinoflagellate population development including toxigenic species and their toxins

33. Maladie du greffon contre l’hôte chronique photo-induite

34. Photochimio-extracorporelle et GVH chronique cutanéo-muqueuse : évaluation clinique à 6mois de traitement

35. Cetuximab plus platinum-based chemotherapy in elderly patients with recurrent or metastatic head and neck squamous cell carcinoma: A French experience from a single institution

37. Immunosuppresseurs dans la prévention de la réaction du greffon contre l’hôte : rapport de la SFGM-TC

41. Conciliation médicamenteuse en médecine interne gériatrique : une collaboration efficace médecins – pharmaciens pour prévenir la iatrogénèse médicamenteuse. Étude prospective de 200 patients

42. Conduite à tenir devant un problème du donneur de cellules souches hématopoïétiques : test de grossesse positif et gammapathie monoclonale

43. Conduite à tenir devant une anomalie biologique découverte lors du bilan pré-don cellules souches hématopoïétiques : sérologie IgM positive pour le cytomégalovirus, le virus d’Epstein-Barr, la toxoplasmose, ou la syphilis

47. CO.133 Association Cetuximab-FOLFIRI en traitement de 1re intention du cancer colorectal métastatique : données de survie et impact du statut KRas de l’étude CRYSTAL

49. Résultats à long terme d'une série de 89 patients suivis pour un sarcome des tissus mous traités par chirurgie conservatrice et trois modalités d'irradiation postopératoire

Catalog

Books, media, physical & digital resources